ESMO Congress | Conference

Atezolizumab Plus Cabozantinib Shows Meaningful Clinical Activity in mCRPC, Including High-Risk Subsets

September 19th 2021

The phase 1b COSMIC-021 trial showed clinically meaningful activity with cabozantinib plus atezolizumab in patients with locally advanced or metastatic castration-resistant prostate cancer who have been previously treated, including patients with high-risk features.

Dr. Garassino on Subgroup Analyses of the VISION Trial in METex14-Altered NSCLC

September 18th 2021

Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.

Pembrolizumab/Chemo With or Without Bevacizumab May Represent New Frontline SOC in Cervical Cancer

September 18th 2021

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates in patients with persistent, recurrent, or metastatic cervical cancer.

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

September 18th 2021

Adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma.

Pembrolizumab/Olaparib Combo May Improve PSA Response Regardless of HRR Mutation Status in mCRPC

September 18th 2021

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

Pembrolizumab/Olaparib Combo Shows Promising Antitumor Activity in mCRPC

September 18th 2021

The combination of pembrolizumab plus olaparib produced promising antitumor activity in men with molecularly unselected docetaxel-pretreated metastatic castration-resistant prostate cancer.

Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC

September 18th 2021

Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial.

Relatlimab/Nivolumab Improves TFI and PFS2 in Frontline Advanced Melanoma

September 18th 2021

The addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone in previously untreated patients with metastatic or unresectable melanoma.

Osimertinib/Bevacizumab Combo Does Not Improve PFS in EGFR-Mutant NSCLC

September 18th 2021

The combination of osimertinib and bevacizumab did not produce a superior progression-free survival benefit vs osimertinib alone in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation.

Trastuzumab Deruxtecan Impresses With Clinical Activity in HER2-Mutant NSCLC

September 18th 2021

Fam-trastuzumab deruxtecan-nxki showcased robust and durable antitumor activity in previously treated patients with HER2-mutant non–small cell lung cancer.

Dr. Monk on Transformative KEYNOTE-826 Data in Frontline Cervical Cancer

September 18th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Cabozantinib Demonstrates Real-World OS Benefit in Second-Line RCC

September 18th 2021

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

Perioperative Cabozantinib Yields Promising Results in mRCC

September 18th 2021

Perioperative treatment with cabozantinib induced responses in patients with intermediate and poor-risk metastatic renal cell carcinoma

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

September 17th 2021

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

September 17th 2021

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

Nivolumab/Ipilimumab Demonstrates Superior Likelihood of Long-Term Survival Vs Sunitinib in Advanced RCC

September 17th 2021

Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.

Toripalimab/Chemo Combo Elicits Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma

September 17th 2021

The addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Olaparib Plus Bipolar Androgen Therapy Showcases Clinical Activity Within Prostate Cancer

September 17th 2021

Combining the PARP inhibitor olaparib with bipolar androgen therapy demonstrated promising clinical activity in patients with castration-resistant prostate cancer.

Olaparib Rechallenge Improves PFS in Relapsed Ovarian Cancer Previously Treated With PARP Inhibition

September 17th 2021

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

Frontline Nivolumab/Ipilimumab Maintains OS Benefit Across Subgroups in Unresectable Malignant Pleural Mesothelioma

September 17th 2021

The frontline combination of nivolumab and ipilimumab continued to demonstrate improved overall survival across subgroups compared with standard chemotherapy at 3 years in patients with unresectable malignant pleural mesothelioma.